{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T19:57:28Z","timestamp":1776715048790,"version":"3.51.2"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2016,3,10]],"date-time":"2016-03-10T00:00:00Z","timestamp":1457568000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurooncol"],"published-print":{"date-parts":[[2016,6]]},"DOI":"10.1007\/s11060-016-2104-2","type":"journal-article","created":{"date-parts":[[2016,3,10]],"date-time":"2016-03-10T12:32:25Z","timestamp":1457613145000},"page":"259-266","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":73,"title":["A phase I study to repurpose disulfiram in combination with temozolomide to treat newly diagnosed glioblastoma after chemoradiotherapy"],"prefix":"10.1007","volume":"128","author":[{"given":"Jiayi","family":"Huang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jian L.","family":"Campian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amit D.","family":"Gujar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David D.","family":"Tran","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A. Craig","family":"Lockhart","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Todd A.","family":"DeWees","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christina I.","family":"Tsien","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Albert H.","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,3,10]]},"reference":[{"key":"2104_CR1","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1007\/s11060-011-0749-4","volume":"107","author":"DR Johnson","year":"2012","unstructured":"Johnson DR, O\u2019Neill BP (2012) Glioblastoma survival in the United States before and during the temozolomide era. J Neurooncol 107:359\u2013364. doi: 10.1007\/s11060-011-0749-4","journal-title":"J Neurooncol"},{"key":"2104_CR2","unstructured":"CBTRUS Statistical Report (2011): primary brain and central nervous system tumors diagnosed in the United States in 2004\u20132007. www.cbtrus.org"},{"key":"2104_CR3","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJMoa043330","volume":"352","author":"R Stupp","year":"2005","unstructured":"Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E, Mirimanoff RO (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987\u2013996. doi: 10.1056\/NEJMoa043330","journal-title":"N Engl J Med"},{"key":"2104_CR4","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1200\/JCO.2006.09.0803","volume":"25","author":"JA DiMasi","year":"2007","unstructured":"DiMasi JA, Grabowski HG (2007) Economics of new oncology drug development. J Clin Oncol 25:209\u2013216. doi: 10.1200\/JCO.2006.09.0803","journal-title":"J Clin Oncol"},{"key":"2104_CR5","doi-asserted-by":"crossref","first-page":"442","DOI":"10.3332\/ecancer.2014.485","volume":"8","author":"P Pantziarka","year":"2014","unstructured":"Pantziarka P, Bouche G, Meheus L, Sukhatme V, Sukhatme VP, Vikas P (2014) The repurposing drugs in oncology (ReDO) project. Ecancermedicalscience 8:442. doi: 10.3332\/ecancer.2014.442","journal-title":"Ecancermedicalscience"},{"key":"2104_CR6","doi-asserted-by":"crossref","first-page":"290","DOI":"10.4103\/0975-7406.72128","volume":"2","author":"A Sharma","year":"2010","unstructured":"Sharma A, Jacob A, Tandon M, Kumar D (2010) Orphan drug: development trends and strategies. J Pharm Bioallied Sci 2:290\u2013299. doi: 10.4103\/0975-7406.72128","journal-title":"J Pharm Bioallied Sci"},{"key":"2104_CR7","doi-asserted-by":"crossref","first-page":"502","DOI":"10.18632\/oncotarget.969","volume":"4","author":"RE Kast","year":"2013","unstructured":"Kast RE, Boockvar JA, Bruning A, Cappello F, Chang WW, Cvek B, Dou QP, Duenas-Gonzalez A, Efferth T, Focosi D, Ghaffari SH, Karpel-Massler G, Ketola K, Khoshnevisan A, Keizman D, Magne N, Marosi C, McDonald K, Munoz M, Paranjpe A, Pourgholami MH, Sardi I, Sella A, Srivenugopal KS, Tuccori M, Wang W, Wirtz CR, Halatsch ME (2013) A conceptually new treatment approach for relapsed glioblastoma: coordinated undermining of survival paths with nine repurposed drugs (CUSP9) by the International Initiative for Accelerated Improvement of Glioblastoma Care. Oncotarget 4:502\u2013530","journal-title":"Oncotarget"},{"key":"2104_CR8","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1002\/stem.1956","volume":"33","author":"J Triscott","year":"2015","unstructured":"Triscott J, Rose Pambid M, Dunn SE (2015) Concise review: bullseye: targeting cancer stem cells to improve the treatment of gliomas by repurposing disulfiram. Stem Cells 33:1042\u20131046. doi: 10.1002\/stem.1956","journal-title":"Stem Cells"},{"key":"2104_CR9","first-page":"543","volume":"21","author":"MD Faiman","year":"1978","unstructured":"Faiman MD, Dodd DE, Hanzlik RE (1978) Distribution of S35 disulfiram and metabolites in mice, and metabolism of S35 disulfiram in the dog. Res Commun Chem Pathol Pharmacol 21:543\u2013567","journal-title":"Res Commun Chem Pathol Pharmacol"},{"key":"2104_CR10","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1097\/01.jcp.0000222512.25649.08","volume":"26","author":"JJ Suh","year":"2006","unstructured":"Suh JJ, Pettinati HM, Kampman KM, O\u2019Brien CP (2006) The status of disulfiram: a half of a century later. J Clin Psychopharmacol 26:290\u2013302. doi: 10.1097\/01.jcp.0000222512.25649.08","journal-title":"J Clin Psychopharmacol"},{"key":"2104_CR11","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.18632\/oncotarget.707","volume":"3","author":"P Hothi","year":"2012","unstructured":"Hothi P, Martins TJ, Chen L, Deleyrolle L, Yoon JG, Reynolds B, Foltz G (2012) High-throughput chemical screens identify disulfiram as an inhibitor of human glioblastoma stem cells. Oncotarget 3:1124\u20131136","journal-title":"Oncotarget"},{"key":"2104_CR12","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1038\/bjc.2012.442","volume":"107","author":"P Liu","year":"2012","unstructured":"Liu P, Brown S, Goktug T, Channathodiyil P, Kannappan V, Hugnot JP, Guichet PO, Bian X, Armesilla AL, Darling JL, Wang W (2012) Cytotoxic effect of disulfiram\/copper on human glioblastoma cell lines and ALDH-positive cancer-stem-like cells. Br J Cancer 107:1488\u20131497. doi: 10.1038\/bjc.2012.442","journal-title":"Br J Cancer"},{"key":"2104_CR13","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.18632\/oncotarget.604","volume":"3","author":"J Triscott","year":"2012","unstructured":"Triscott J, Lee C, Hu K, Fotovati A, Berns R, Pambid M, Luk M, Kast RE, Kong E, Toyota E, Yip S, Toyota B, Dunn SE (2012) Disulfiram, a drug widely used to control alcoholism, suppresses the self-renewal of glioblastoma and over-rides resistance to temozolomide. Oncotarget 3:1112\u20131123","journal-title":"Oncotarget"},{"key":"2104_CR14","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1038\/nature05236","volume":"444","author":"S Bao","year":"2006","unstructured":"Bao S, Wu Q, McLendon RE, Hao Y, Shi Q, Hjelmeland AB, Dewhirst MW, Bigner DD, Rich JN (2006) Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 444:756\u2013760. doi: 10.1038\/nature05236","journal-title":"Nature"},{"key":"2104_CR15","doi-asserted-by":"crossref","first-page":"10425","DOI":"10.1158\/0008-5472.CAN-06-2126","volume":"66","author":"D Chen","year":"2006","unstructured":"Chen D, Cui QC, Yang H, Dou QP (2006) Disulfiram, a clinically used anti-alcoholism drug and copper-binding agent, induces apoptotic cell death in breast cancer cultures and xenografts via inhibition of the proteasome activity. Cancer Res 66:10425\u201310433. doi: 10.1158\/0008-5472.CAN-06-2126","journal-title":"Cancer Res"},{"key":"2104_CR16","doi-asserted-by":"crossref","first-page":"6256","DOI":"10.1021\/jm8007807","volume":"51","author":"B Cvek","year":"2008","unstructured":"Cvek B, Milacic V, Taraba J, Dou QP (2008) Ni(II), Cu(II), and Zn(II) diethyldithiocarbamate complexes show various activities against the proteasome in breast cancer cells. J Med Chem 51:6256\u20136258. doi: 10.1021\/jm8007807","journal-title":"J Med Chem"},{"issue":"(Suppl 3)","key":"2104_CR17","first-page":"iii52","volume":"15","author":"X Lun","year":"2013","unstructured":"Lun X, Wells JC, Hao X, Zhang J, Grinshtein N, Kaplan D, Luchman A, Weiss S, Cairncross JG, Senger DS, Robbins S (2013) Disulfiram when combined with copper is an effective adjuvant therapy with TMZ for treatment of human gliomblastoma. Neuro-oncology 15(Suppl 3):iii52 [Abstract: ET-064]","journal-title":"Neuro-oncology"},{"key":"2104_CR18","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1093\/carcin\/bgt366","volume":"35","author":"A Paranjpe","year":"2014","unstructured":"Paranjpe A, Zhang R, Ali-Osman F, Bobustuc GC, Srivenugopal KS (2014) Disulfiram is a direct and potent inhibitor of human O6-methylguanine-DNA methyltransferase (MGMT) in brain tumor cells and mouse brain and markedly increases the alkylating DNA damage. Carcinogenesis 35:692\u2013702. doi: 10.1093\/carcin\/bgt366","journal-title":"Carcinogenesis"},{"key":"2104_CR19","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1200\/JCO.2009.26.3541","volume":"28","author":"PY Wen","year":"2010","unstructured":"Wen PY, Macdonald DR, Reardon DA, Cloughesy TF, Sorensen AG, Galanis E, Degroot J, Wick W, Gilbert MR, Lassman AB, Tsien C, Mikkelsen T, Wong ET, Chamberlain MC, Stupp R, Lamborn KR, Vogelbaum MA, van den Bent MJ, Chang SM (2010) Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol 28:1963\u20131972. doi: 10.1200\/JCO.2009.26.3541","journal-title":"J Clin Oncol"},{"key":"2104_CR20","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1093\/clinchem\/46.5.673","volume":"46","author":"ES Lightcap","year":"2000","unstructured":"Lightcap ES, McCormack TA, Pien CS, Chau V, Adams J, Elliott PJ (2000) Proteasome inhibition measurements: clinical application. Clin Chem 46:673\u2013683","journal-title":"Clin Chem"},{"key":"2104_CR21","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/S1470-2045(11)70081-X","volume":"12","author":"P Moreau","year":"2011","unstructured":"Moreau P, Pylypenko H, Grosicki S, Karamanesht I, Leleu X, Grishunina M, Rekhtman G, Masliak Z, Robak T, Shubina A, Arnulf B, Kropff M, Cavet J, Esseltine DL, Feng H, Girgis S, van de Velde H, Deraedt W, Harousseau JL (2011) Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study. Lancet Oncol 12:431\u2013440. doi: 10.1016\/S1470-2045(11)70081-X","journal-title":"Lancet Oncol"},{"key":"2104_CR22","doi-asserted-by":"crossref","first-page":"4420","DOI":"10.1200\/JCO.2002.01.133","volume":"20","author":"RZ Orlowski","year":"2002","unstructured":"Orlowski RZ, Stinchcombe TE, Mitchell BS, Shea TC, Baldwin AS, Stahl S, Adams J, Esseltine DL, Elliott PJ, Pien CS, Guerciolini R, Anderson JK, Depcik-Smith ND, Bhagat R, Lehman MJ, Novick SC, O\u2019Connor OA, Soignet SL (2002) Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies. J Clin Oncol 20:4420\u20134427","journal-title":"J Clin Oncol"},{"key":"2104_CR23","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1038\/pcan.2013.28","volume":"16","author":"MT Schweizer","year":"2013","unstructured":"Schweizer MT, Lin J, Blackford A, Bardia A, King S, Armstrong AJ, Rudek MA, Yegnasubramanian S, Carducci MA (2013) Pharmacodynamic study of disulfiram in men with non-metastatic recurrent prostate cancer. Prostate Cancer Prostatic Dis 16:357\u2013361. doi: 10.1038\/pcan.2013.28","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"2104_CR24","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1097\/00000421-198712000-00012","volume":"10","author":"DJ Stewart","year":"1987","unstructured":"Stewart DJ, Verma S, Maroun JA (1987) Phase I study of the combination of disulfiram with cisplatin. Am J Clin Oncol 10:517\u2013519","journal-title":"Am J Clin Oncol"},{"key":"2104_CR25","first-page":"265","volume":"409","author":"GE Nilsson","year":"1987","unstructured":"Nilsson GE, Tottmar O, Wahlstrom G (1987) Effects of aldehyde dehydrogenase inhibitors on hexobarbital sensitivity and neuroamine metabolism in rat brain. Brain Res 409:265\u2013274","journal-title":"Brain Res"},{"key":"2104_CR26","first-page":"337","volume":"14","author":"LF Major","year":"1979","unstructured":"Major LF, Lerner P, Ballenger JC, Brown GL, Goodwin FK, Lovenberg W (1979) Dopamine-beta-hydroxylase in the cerebrospinal fluid: relationship to disulfiram-induced psychosis. Biol Psychiatry 14:337\u2013344","journal-title":"Biol Psychiatry"},{"key":"2104_CR27","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1038\/clpt.1984.213","volume":"36","author":"MD Faiman","year":"1984","unstructured":"Faiman MD, Jensen JC, Lacoursiere RB (1984) Elimination kinetics of disulfiram in alcoholics after single and repeated doses. Clin Pharmacol Ther 36:520\u2013526","journal-title":"Clin Pharmacol Ther"},{"key":"2104_CR28","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1093\/neuonc\/nou305","volume":"17","author":"SA Choi","year":"2015","unstructured":"Choi SA, Choi JW, Wang KC, Phi JH, Lee JY, Park KD, Eum D, Park SH, Kim IH, Kim SK (2015) Disulfiram modulates stemness and metabolism of brain tumor initiating cells in atypical teratoid\/rhabdoid tumors. Neuro-oncology 17:810\u2013821. doi: 10.1093\/neuonc\/nou305","journal-title":"Neuro-oncology"},{"key":"2104_CR29","doi-asserted-by":"crossref","first-page":"e78130","DOI":"10.1371\/journal.pone.0078130","volume":"8","author":"SK Kim","year":"2013","unstructured":"Kim SK, Kim H, Lee DH, Kim TS, Kim T, Chung C, Koh GY, Kim H, Lim DS (2013) Reversing the intractable nature of pancreatic cancer by selectively targeting ALDH-high, therapy-resistant cancer cells. PLoS One 8:e78130. doi: 10.1371\/journal.pone.0078130","journal-title":"PLoS One"},{"key":"2104_CR30","doi-asserted-by":"crossref","first-page":"4085","DOI":"10.1200\/JCO.2013.49.6968","volume":"31","author":"MR Gilbert","year":"2013","unstructured":"Gilbert MR, Wang M, Aldape KD, Stupp R, Hegi ME, Jaeckle KA, Armstrong TS, Wefel JS, Won M, Blumenthal DT, Mahajan A, Schultz CJ, Erridge S, Baumert B, Hopkins KI, Tzuk-Shina T, Brown PD, Chakravarti A, Curran WJ Jr, Mehta MP (2013) Dose-dense temozolomide for newly diagnosed glioblastoma: a randomized phase III clinical trial. J Clin Oncol 31:4085\u20134091. doi: 10.1200\/JCO.2013.49.6968","journal-title":"J Clin Oncol"},{"key":"2104_CR31","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1056\/NEJMoa1308573","volume":"370","author":"MR Gilbert","year":"2014","unstructured":"Gilbert MR, Dignam JJ, Armstrong TS, Wefel JS, Blumenthal DT, Vogelbaum MA, Colman H, Chakravarti A, Pugh S, Won M, Jeraj R, Brown PD, Jaeckle KA, Schiff D, Stieber VW, Brachman DG, Werner-Wasik M, Tremont-Lukats IW, Sulman EP, Aldape KD, Curran WJ Jr, Mehta MP (2014) A randomized trial of bevacizumab for newly diagnosed glioblastoma. N Engl J Med 370:699\u2013708. doi: 10.1056\/NEJMoa1308573","journal-title":"N Engl J Med"}],"container-title":["Journal of Neuro-Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-016-2104-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11060-016-2104-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-016-2104-2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,16]],"date-time":"2020-09-16T23:43:32Z","timestamp":1600299812000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11060-016-2104-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,3,10]]},"references-count":31,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2016,6]]}},"alternative-id":["2104"],"URL":"https:\/\/doi.org\/10.1007\/s11060-016-2104-2","relation":{},"ISSN":["0167-594X","1573-7373"],"issn-type":[{"value":"0167-594X","type":"print"},{"value":"1573-7373","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,3,10]]}}}